This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

ICD-10 G31.02 — Nonfluent variant primary progressive aphasia Special Copayment Reduction: V800

Nonfluent/agrammatic variant primary progressive aphasia, nfvPPA비유창변이 원발성 진행성 실어증

Synonyms and related terms: Progressive nonfluent aphasia (PNFA), nonfluent/agrammatic PPA

Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

The clinical description of nonfluent/agrammatic variant PPA (nfvPPA) begins in 1982 with Marsel Mesulam, who reported six cases showing mainly a gradually progressive language disorder alone and named it "progressive aphasia without dementia." This early report emphasized an isolated decline in language function with other cognitive functions preserved for several years or more. Subsequently, in the 1990s, researchers in the line of Brenda Milner systematically classified a subtype characterized by impaired speech fluency and grammatical structure.

In the 1994 Lund-Manchester criteria, progressive nonfluent aphasia (PNFA) was included as a language variant of FTD, and it was also recognized as an independent clinical subtype in the 2004 classification by Neary et al. In the 2011 international PPA classification criteria of Gorno-Tempini et al., a three-subtype system was formalized: nonfluent/agrammatic PPA, semantic variant PPA, and logopenic variant PPA. The underlying neuropathology is mostly FTLD-tau (corticobasal degeneration or PSP pathology), and FTLD-TDP type A or Alzheimer pathology is rarely reported. It is classified as G31.02 in Korean ICD-10.

2. Causes

The underlying neuropathology of nfvPPA is diverse, but the most common is FTLD-tau, and among these, corticobasal degeneration (CBD) pathology and progressive supranuclear palsy (PSP) pathology are the main underlying etiologies. In CBD pathology, 4R tau-predominant astrocytic plaques, coiled bodies, and ballooned neurons are concentrated in the left frontoparietal cortex, and in PSP pathology, 4R tau-predominant neurofibrillary tangles (tufted astrocytes) are distributed in the basal ganglia, brainstem, and frontal lobe.

Rarely, FTLD-TDP type A (associated with GRN variants) or Alzheimer pathology (dual amyloid and tau pathology) can be the underlying cause of nfvPPA. Therefore, predicting pathology during life is difficult in individual cases of nfvPPA, and understanding the pathology-specific characteristics of CSF biomarkers and tau PET is important. Most cases are sporadic, and in familial cases MAPT variants (rarely with a language-predominant phenotype) and GRN variants are reported.

3. Genetics

As familial causes of nfvPPA, MAPT variants (especially splicing variants causing overproduction of 4R tau), GRN variants (nfvPPA phenotype in some cases), and C9orf72 repeat expansion (a few cases) are reported. However, nfvPPA has a relatively high proportion of sporadic cases across the FTD spectrum, and cases with a family history are fewer than in bvFTD. The 4R tau pathology related to CBD and PSP is mostly sporadic, and genetic causes are rare.

When there is a family history, genetic testing starts with the FTD panel (including MAPT, GRN, and C9orf72). When a GRN variant is identified, measurement of plasma progranulin concentration is used as a screening test. The MAPT H1/H1 haplotype homozygote is associated with sporadic risk of CBD and PSP and is used in the pathobiological understanding of nfvPPA.

4. General epidemiology

nfvPPA accounts for about 20-30% of all PPA and about 10-15% of the FTD spectrum. The age of onset is usually in the 50s-70s, similar to the other PPA variants (svPPA, lvPPA). The sex distribution is generally equal, or female predominance has been reported in some cohorts. The prevalence of all PPA is estimated at about 5-10 per 100,000, of which nfvPPA accounts for about 1-3. Domestic statistics are included in overall FTD statistics, so separate data are limited.

Because the clinical course differs by type of underlying pathology, biomarker research for predicting pathology during life is actively under way. CBD-based nfvPPA may acquire the motor symptoms of corticobasal syndrome (CBS) as it progresses, and PSP-based cases may add vertical supranuclear palsy and postural instability. The clinical overlap of nfvPPA with CBD and PSP within the FTD spectrum requires a complex diagnostic process.

5. Pathophysiology

The core pathological sites of nfvPPA are neurodegeneration of the left posterior frontal lobe—especially Broca's area (BA 44/45)—and the left insula. These regions are central to speech motor planning, articulatory coordination, and syntactic processing, and neuronal loss and synaptic damage here lead to non-fluent speech and impaired syntactic comprehension and production.

In FTLD-tau pathology, 4R tau (CBD or PSP type) forms intraneuronal NFTs together with tau pathology of astrocytes and oligodendrocytes (CBD: astrocytic plaques, coiled bodies; PSP: tufted astrocytes), causing extensive damage to gray and white matter. Structural damage to the left-dominant frontoparietal network (frontal-insular-parietal) is associated with apraxia of speech and agrammatism. The neuroanatomical basis of apraxia of speech is associated with the left supplementary motor area (SMA), premotor cortex (PMC), and left posterior insula, and early involvement of these structures is characteristic in nfvPPA.

6. Symptoms

The main clinical symptom of nfvPPA is non-fluent speech, with effortfulness, hesitation, phonological errors (consonant/vowel substitution, addition, omission), and reduced articulation when attempting to speak. Apraxia of speech: inconsistent articulatory errors, self-correction attempts of positional errors, and increased errors in complex phonological sequences are characteristic. Agrammatism: telegraphic speech due to omission or substitution of particles, endings, and grammatical morphemes, impaired comprehension of complex sentences, and reduced comprehension of passive voice and relative clauses appear.

In contrast, word meaning knowledge is relatively preserved early, so the naming impairment or word comprehension impairment seen in svPPA is not prominent early. In reading, irregular-word reading errors appear less than in phonological rule-based reading irrespective of meaning (phonological dyslexia), which contrasts with the surface dyslexia of svPPA. In writing, grammatical errors are more prominent than spelling errors. Early on, the impairment is confined to language function with other cognitive functions preserved, but as the disease progresses, executive function decline and motor symptoms (CBS, PSP patterns) are added.

7. Signs

On neurological examination in early nfvPPA, non-fluent spontaneous speech, effortfulness, and phonological errors are observed. Searching pauses during speech, sound/syllable repetition, and self-correction attempts are typical expressions of apraxia of speech. On verbal repetition testing, errors are marked on repetition of long multisyllabic words or nonsense words, while short words are repeated relatively well. On sentence comprehension testing, impaired comprehension of complex grammatical structures (relative clauses, passive voice) is confirmed.

On standardized language tests (WAB, Token Test, syntax comprehension test), a specific decline pattern is found in spontaneous speech scores (fluency item), naming (basically preserved, declining with progression), and comprehension of complex sentences. The pattern in which phonemic fluency (generating words beginning with a specific consonant) is reduced more than semantic fluency contrasts with svPPA. With progression, corticobasal syndrome (alien limb, myoclonus, apraxia, cortical sensory abnormalities) or PSP signs (vertical supranuclear palsy, postural instability, axial rigidity) are added.

8. Screening

For screening of nfvPPA, language tests reflecting non-fluent speech and agrammatism are key. Observation of speech fluency: In free speech or a picture description task (describing the Cookie Theft picture), observe speech rate, effortfulness, phonological errors, and the presence of grammatical omissions. Phonemic fluency: The number of words generated in 1 minute beginning with a specific consonant (e.g., Korean consonants 'g' and 's') shows a specific pattern of being reduced more than semantic fluency in nfvPPA. Sentence repetition test: Errors are prominent on repetition of complex sentences, which is useful for screening for apraxia of speech.

Analysis of the spontaneous speech, naming, repetition, and comprehension subitems of the Seoul Neuropsychological Screening Battery (SNSB) or K-WAB quantifies the neuropsychological profile of nfvPPA. The presence of left posterior frontal-insular atrophy on brain MRI and a left frontal-insular hypometabolism pattern on FDG-PET support nfvPPA. Tau PET (18F-flortaucipir, 18F-PI-2620) is being used at the clinical research stage to detect 4R tau pathology (CBD, PSP).

9. Diagnosis

The diagnosis of nfvPPA follows the 2011 international PPA classification criteria of Gorno-Tempini et al. For the core diagnostic criteria, at least one of ① apraxia of speech or ② agrammatism in language production must be met. Supportive diagnostic features include ③ impaired syntax comprehension or word decoding (especially for grammatically complex syntax), ④ impaired word generation with reduced speech motor programming, and ⑤ phonological errors in speech. Early preservation of word meaning knowledge is the key differentiating point from svPPA.

Imaging supportive criteria include left posterior frontal-insular atrophy on MRI, hypometabolism of the same region on FDG-PET, and hypoperfusion on SPECT. Exclusion of Alzheimer pathology on CSF biomarkers (normal Aβ42, normal or mildly elevated p-tau) supports FTLD pathology. Binding of a 4R tau-selective tracer (18F-PI-2620) on tau PET suggests CBD- or PSP-based FTLD-tau. Pathological confirmation is made by identification of 4R tau pathology (CBD: astrocytic plaques, PSP: tufted astrocytes) in autopsy or biopsy tissue.

10. Treatment

There is no approved disease-modifying treatment for nfvPPA, and symptomatic therapy aimed at preserving language function and maintaining communication ability is key. For speech-language therapy, articulatory-kinematic therapy for apraxia of speech, speech rate control, and melodic intonation therapy (MIT) have shown short-term effects in some small studies. Grammar treatment (treatment of underlying forms, TUF) has been reported to produce some generalization effects through training in producing and comprehending complex sentence structures.

Early introduction of augmentative and alternative communication (AAC) systems before speech ability declines is important, and various communication strategies using picture cards, speech-generating devices, and tablet AAC apps are used. "Voice banking" technology in preparation for progressive language loss—recording the individual's voice in advance and loading it onto an AAC device—may also be applied. When motor symptoms (CBS, PSP patterns) accompany, physical therapy, occupational therapy, and fall prevention education for these symptoms are added. As for drug treatment, cholinesterase inhibitors show no significant effect in nfvPPA, and SSRIs are used when behavioral symptoms accompany.

11. Prognosis

nfvPPA is a progressive neurodegenerative disease with a poor prognosis. Survival from symptom onset to death is reported as about 6-12 years, but varies with the type of underlying pathology. During progression, gradual loss of speech function, mutism, and dysphagia occur, and in CBD- or PSP-based cases, functional decline accelerates due to motor complications (falls, limb rigidity, dysphagia). The prognosis is even poorer when FTD-ALS overlap is present.

For tracking functional level, the PPA Severity Rating Scale, the Western Aphasia Battery (WAB), and the CDR plus FTLD sum of boxes score are used. The rate of decline in speech function varies greatly between individuals depending on the type of underlying pathology and the anatomical distribution of lesions. Early AAC introduction and continued speech-language therapy contribute to preserving communication function and quality of life, and advance decision-making and preparation of a life-sustaining treatment plan before communication ability declines are recommended.

12. Prevention

There is no established primary prevention for nfvPPA. When a causative variant is identified in a familial case, genetic counseling and predictive testing can be offered to adult family members, and counseling accompanied by a mental health professional should come first. For general brain health promotion, management of cardiovascular risk factors, regular exercise, social participation, and lifelong language education are recommended. Prevention of head trauma is also recommended in terms of reducing risk across the FTLD spectrum. Starting speech-language therapy after early diagnosis, AAC planning, and linkage to family support programs are important for adaptation to the disease and maintenance of function.

13. References